SEC Form 4 · accession 0001437749-26-023570
Eton Pharmaceuticals, Inc. · ETON
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sean Brynjelsen
Officer — President & CEO · Director
Period of report
Jul 12, 2026
Accepted (ET)
Jul 14, 2026 · 5:28 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001710340
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jul 12, 2026 | M | 27,500 | — | A | 861,194 | D | |
| Common Stock | Jul 14, 2026 | M | 200,000 | $1.37 | A | 1,061,194 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1 | $0.00 | Jul 12, 2026 | M | 27,500 | D | — | — | Common Stock | 27,500 | 0 | D |
| Employee Stock OptionF2 | $1.37 | Jul 14, 2026 | M | 200,000 | A | Nov 10, 2017 | Nov 9, 2027 | Common Stock | 200,000 | 0 | D |
Explanation of responses
- F1On July 12, 2022, the reporting person was granted 110,000 restricted stock units which vested in four equal installments beginning July 12, 2023.
- F2The shares subject to the option vested annually from the date of grant (11-10-2017) in four equal installments.
Remarks
The reporting person has authorized and designated the named person to file this Form 4 on the reporting person's behalf for an indefinite duration.